Chembio Diagnostics, Inc. announced the submission of an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for the new DPP SARS-CoV-2 Antigen test. Previously, Chembio received an award from the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services? Office of the Assistant Secretary for Preparedness and Response, to assist in developing a COVID-19 point-of-care antigen test system using Chembio?s proprietary DPP technology and requesting FDA EUA for the test system. The DPP SARS-CoV-2 Antigen test system has been designed to detect SARS-CoV-2 antigens in only 20 minutes. The DPP SARS-CoV-2 Antigen test system is now designed to use a minimally invasive nasal swab and be read visually or with a DPP Micro Reader or DPP Micro Reader 2 optical analyzer.